ClinicalTrials.gg
RecruitingNCT06942143Updated Sep 3, 2025

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors

A Phase 1 interventional study of Super1 TCR-T in Sarcoma, Lung Cancers and Melanoma, sponsored by Guangzhou FineImmune Biotechnology Co., LTD.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Guangzhou FineImmune Biotechnology Co., LTD. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Sarcoma with a site in China — 68 open to participants now, 74 under way, 1 of them phase 3. Sarcoma · China.

Planned enrollment
107th of 122
15 · median 45
Started
2025
with 10 others
Phase 1
23 of 133
14 open now
Primary completion
2027-04
later than 43 of 73 live
Registered
107th of 133
by date

Among the 133 studies in Sarcoma with a site in China, this one is the 107th largest by planned enrollment of the 122 interventional ones that give a count, is one of 11 that started in 2025, is one of 23 in phase 1, reaches primary completion later than 43 of the 73 other live ones, and was the 107th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

68 of the 133 studies in Sarcoma with a site in China are open now. Recruiting first, the newest first:

62 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Sarcoma with a site in China, or all of them as a file.
02

Study summary

This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.

Read the detailed description

After the subjects signed the informed consent form, the HLA genotype of the subjects was detected. After the HLA genotype was confirmed as A*02, the tumor tissue was detected by immunohistochemistry. The subjects could proceed to the subsequent clinical trial if the NY-ESO-1 immunohistochemistry was positive. Each subject received only one cell reinfusion.

03

Conditions studied

  • Sarcoma
  • Lung Cancers
  • Melanoma

Keywords

  • Cell therapy
  • Immunotherapy
  • Solid tumor
  • NY-ESO-1 TCR-T
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign before conducting any trial-related activities;
  2. Age of 18-75 years old, male or female;
  3. Patients with treatment failure;
  4. according to RECIST1.1 criteria.
  5. During the trial screening period, the following two screening criteria must be met (by the sponsor) :

    • HLA-A*02 positive;
    • The positive rate of NYESO-1 immunohistochemical staining was ≥20%.
  6. score 0-1;
  7. The expected survival time is more than 3 months;
  8. Antineoplastic drugs and treatments were not allowed for 4 weeks before TCR-T cell infusion;
  9. Echocardiography showed ≥50%;
  10. Laboratory test results should at least meet the following specified indicators:

    • WBC ≥3.0×109/L;
    • (ANC) ≥1.5×109/L;
    • Absolute lymphocyte count (ALC) ≥1.0×109/L;
    • (PLT) ≥75×109/L;
    • ≥10g/dL (no blood transfusion in the past 7 days);
    • or INR≤1.5x unless receiving anticoagulant therapy;
    • Partial prothrombin time (APTT) ≤1.5x upper limit of normal time, unless receiving anticoagulant therapy;
    • 24-hour ≥60mL/ min;
    • (AST/SGOT) ≤2.5×ULN;
    • alanine aminotransferase (ALT/SGPT) ≤2.5×ULN;
    • Total (TBIL) ≤1.5×ULN
  11. Negative pregnancy tests in women of prior to study treatment; Consent must be given to use effective during treatment.
  12. During the whole period of the trial, I can regularly visit the enrolled research institutions for relevant testing, evaluation and management.

Exclusion criteria

Exclusion Criteria:

  1. Patients who received major surgery, conventional chemotherapy, large area radiotherapy, immunotherapy or biological therapy within 4 weeks before entering the trial;
  2. Known to produce allergic reactions to any component of the trial treatment;
  3. no recovery from previous surgery or treatment-related adverse events to ≤ grade 2 ;
  4. Poorly controlled hypertension (systolic blood pressure > 160mmHg and/or diastolic blood pressure > 90mmHg) or (e.g., active) cardio-cerebrovascular disease; Cerebrovascular accident (within 6 months before the signing of ), myocardial infarction (within 6 months before the signing of informed consent), unstable angina, congestive heart failure of class II or higher (Appendix), or severe arrhythmia that could not be controlled with medications or that had the potential to affect study treatment; (ECG) was significantly abnormal or the mean was ≥450 msec on three consecutive occasions.
  5. Combined with other serious organic diseases and mental disorders;
  6. Have active systemic infection requiring treatment, including active tuberculosis, known positivity, or clinically active hepatitis A, B, or C; (Virus carriers should be excluded)
  7. Patients with diseases: those with a history of inflammatory bowel disease or a history of autoimmune diseases (such as systemic lupus erythematosus, vasculitis, and invasive lung disease) judged by the investigators to be not suitable for this study should be excluded; (Patients with vitiligo are not excluded).
  8. Administration of chronic systemic cortisone , hydroxyurea, and immunomodulatory agents (e.g., interleukin-2, interferon-α or γ, GM-CSF, mTOR inhibitors, cyclosporine, thymosin, etc.) within 4 weeks prior to cell therapy."
  9. History of organ transplantation, /allogeneic stem cell transplantation and renal replacement therapy;
  10. Known uncontrolled diabetes mellitus, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure;
  11. Known alcohol and/or drug abuse;
  12. Pregnant or lactating women;
  13. Trial participants with any coexisting medical conditions or diseases judged by the investigators to be likely to impair the conduct of the trial;
  14. No legal capacity/limited capacity.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Dose escalation was performed in a 3+3 design

    The Super1 TCR-T dose toxicity test was escalated according to the following dose (positive cells) escalation schedule: Level 1 Level 2 Level 3

    Biological: Super1 TCR-T

Interventions

  • BiologicalSuper1 TCR-T

    All participators received lymphoid-depleted preconditioning before Super1 TCR-T cells infusion. Super1 TCR-T cells were infused 3 days later. Concomitant administration of interleukin for 7 consecutive days.

    Also known as: NY-ESO-1 TCR-T

06

What researchers measure

Primary outcomes

  1. DLT

    Determining the dose-limiting toxicity (DLT) of Super1 TCR-T adoptive Immunotherapy

    Time frame: Up to 28 Days

  2. MDT

    Determining the maximum Tolerated dose (MTD) of Super1 TCR-T adoptive Immunotherapy

    Time frame: Up to 28 Days

Secondary outcomes

  1. ORR

    Objective response rate,defined as the proportion of subjects with a confirmed PR or better best response

    Time frame: One year after cell reinfusion

  2. OS

    overall survival,time from subject's treatment to death. Participants with no death recorded at the time of statistical analysis were censored at the time of the last follow-up. In cases of loss to follow-up, data were censored at the date of the last contact with the participant.

    Time frame: One year after cell reinfusion

  3. PFS

    progression-free survival ,the time from the subject's treatment to the occurrence of PD or death from any cause, whichever occurred first. If no event (PD or death) occurred, the date of the last response assessment was the censored time for PFS.

    Time frame: One year after cell reinfusion

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Apr 2027, 23 months after the start.

Of 72 industry-sponsored phase 1 interventional studies under Sarcoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 66. This study's planned 23 months is below that.

Counting every sponsor, half of 161 studies reached it within 56 months; a quarter within 35 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 24, 2025
StartActual
May 22, 2025
Primary completionEst.
Apr 25, 2027
CompletionEst.
Jun 25, 2027
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06942143
Lead sponsor
Guangzhou FineImmune Biotechnology Co., LTD.
Collaborators
Sun Yat-Sen University Cancer Center
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
May 22, 2025
Primary completion
Apr 25, 2027 (estimated)
Completion
Jun 25, 2027 (estimated)
Last update
Sep 3, 2025

Study contacts

Ying Cheng
Contact
chengy02@fineimmu.com
86-02031605836 ext. 08613535517727

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion